[1]

National Center for Cardiovascular Diseases. Report on Cardiovascular Health and Diseases in China 2021 (in Chinese). Beijing: Science Press, 2022.

[2] Zhao D, Liu J, Wang M, et al. Epidemiology of cardiovascular disease in China: current features and implications. Nat Rev Cardiol 2019; 16: 203−212. doi: 10.1038/s41569-018-0119-4 [3]

Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017; 38: 2459−2472.

[4]

Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U. S. deaths from coronary disease, 1980-2000. N Engl J Med 2007; 356: 2388−2398.

[5]

Center for Disease Control and Prevention of National Health Commission of the People's Republic of China. Report on Nutrition and Chronic Diseases of Chinese Residents 2015 (in Chinese). Beijing: People's Medical Press, 2015.

[6]

Joint Committee on Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults. Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults. Chin J Cardiol 2007; 35: 390−419. (In Chinese).

[7]

Chinese Cardiovascular Journal Editorial Board Dyslipidemia Prevention and Treatment Countermeasures Special Group. Recommendations for Prevention and Treatment of Dyslipidemia. Chin J Cardiol 1997; 25: 169−172. (In Chinese).

[8]

Joint Committee on Chinese Guideline for the Management of Dyslipidemia in Adults. 2016 Chinese Guideline for the Management of Dyslipidemia in Adults. Chin Circ J 2016; 31: 937−953. (In Chinese).

[9] National Society of Cardiometabolic Medicine. Chinese Expert Recommendations on Lipid Management Options for Community Hospitals (2022 Edition). Chin Circ J 2022; 37: 1181−1185. (In Chinese). doi: 10.3969/j.issn.1000-3614.2022.12.002 [10] Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713−1722. doi: 10.1056/NEJMoa1615664 [11] Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019; 380: 11−22. doi: 10.1056/NEJMoa1812792 [12]

Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139: e1082−e1143.

[13] Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111−188. doi: 10.1093/eurheartj/ehz455 [14] [15] Ding W, Cheng H, Yan Y, et al. 10-year trends in serum lipid levels and dyslipidemia among children and adolescents from several schools in Beijing, China. J Epidemiol 2016; 26: 637−645. doi: 10.2188/jea.JE20140252 [16] Zhang M, Deng Q, Wang L, et al. Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults: A nationally representative survey of 163, 641 adults. Int J Cardiol 2018; 260: 196−203. doi: 10.1016/j.ijcard.2017.12.069 [17]

Song PK, Man QQ, Li H, et al. Trends in lipids level and dyslipidemia among Chinese adults, 2002-2015. Biomed Environ Sci 2019; 32: 559−570.

[18]

Center for Disease Control and Prevention of National Health Commission of the People's Republic of China. Report on Nutrition and Chronic Diseases of Chinese Residents 2020 (in Chinese). Beijing: People's Medical Press, 2020.

[19] NCD Risk Factor Collaboration. Repositioning of the global epicentre of non-optimal cholesterol. Nature 2020; 582: 73−77. doi: 10.1038/s41586-020-2338-1 [20] Moran A, Gu D, Zhao D, et al. Future cardiovascular disease in china: markov model and risk factor scenario projections from the coronary heart disease policy model-China. Circ Cardiovasc Qual Outcomes 2010; 3: 243−252. doi: 10.1161/CIRCOUTCOMES.109.910711 [21] Pan L, Yang Z, Wu Y, et al. The prevalence, awareness, treatment and control of dyslipidemia among adults in China. Atherosclerosis 2016; 248: 2−9. doi: 10.1016/j.atherosclerosis.2016.02.006 [22]

Ding W, Dong H, Mi J. Prevalence of dyslipidemia in Chinese children and adolescents: a Meta-analysis. Chin J Epidemiol 2015; 36: 71−77. (In Chinese).

[23]

Wang Z, Zou Z, Yang Y, et al. The epidemiological characteristics and related factors of dyslipidemia among children and adolescents aged 6-17 years from 7 provinces in China, 2012. Chin J Prev Med 2018; 52: 798−801. (In Chinese).

[24]

China Hypertension Survey and Research Group. Status of dyslipidemia among adults aged 35 years and above in China (in Chinese). Chin Circ J 2019; 34 681-687.

[25]

Atherosclerosis and Coronary Heart Disease Working Group of Chinese Society of Cardiology, Editorial Board of Chinese Journal of Cardiology. Chinese Expert Consensus on Lipid Management of Very High-Risk Atherosclerotic Cardiovascular Disease Patients. Chin J Cardiol 2020; 48: 280−286. (In Chinese).

[26]

Zeng Y, Liu J, Liu J, et al. The expanding needs on lipid-lowering treatment in patients with acute coronary syndrome by applying newly issued definition of extreme high-risk by chinese society of cardiology. Chin J Cardiol 2020; 48: 1039−1046. (In Chinese).

[27] Li S, Liu HH, Guo YL, et al. Improvement of evaluation in Chinese patients with atherosclerotic cardiovascular disease using the very-high-risk refinement: a population-based study. Lancet Reg Health West Pac 2021; 17: 100286. doi: 10.1016/j.lanwpc.2021.100286 [28] Boren J, Chapman MJ, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2020; 41: 2313−2330. doi: 10.1093/eurheartj/ehz962 [29] Ong KL, McClelland RL, Allison MA, et al. Lipoprotein (a) and coronary artery calcification: prospective study assessing interactions with other risk factors. Metabolism 2021; 116: 154706. doi: 10.1016/j.metabol.2021.154706 [30] Li JJ, Ma CS, Zhao D, et al. Lipoprotein(a) and cardiovascular disease in Chinese population: A Beijing Heart Society Expert Scientific Statement. JACC Asia 2022; 2: 653−665. doi: 10.1016/j.jacasi.2022.08.015 [31]

Mehta A, Vasquez N, Ayers CR, et al. Independent association of lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk. J Am Coll Cardiol 2022; 79: 757−768.

[32] Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011; 32: 1345−1361. doi: 10.1093/eurheartj/ehr112 [33] Vallejo-Vaz AJ, Fayyad R, Boekholdt SM, et al. Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial. Circulation 2018; 138: 770−781. doi: 10.1161/CIRCULATIONAHA.117.032318 [34] Chait A, Ginsberg HN, Vaisar T, et al. Remnants of the triglyceride-rich lipoproteins, diabetes, and cardiovascular disease. Diabetes 2020; 69: 508−516. doi: 10.2337/dbi19-0007 [35]

Raposeiras-Roubin S, Rossello X, Oliva B, et al. Triglycerides and residual atherosclerotic risk. J Am Coll Cardiol 2021; 77: 3031−3041.

[36]

Yan S. Recommendations for Clinical Lipid Profile Testing (in Chinese). Chin J Lab Med 2003; 26: 182−184.

[37]

Laboratory Medicine Society of Chinese Medical Association, Branch of Laboratory Physicians of Chinese Medical Doctor Association, Lipids and Lipoproteins Committee, Chinese Society of Biochemistry and Molecular Biology, National Health Commission Clinical Laboratory Center, Editorial Board of Chinese Journal of Laboratory Medicine. China guideline for clinical lipid profile testing. Chin J Lab Med 2022; 45: 1017−1033. (In Chinese).

[38]

Yan S. The link between lipid profile testing and clinical practice should be further strengthened. Chin J Clin Lab Sci 2008; 26: 243−245. (In Chinese).

[39]

Liu L, Zhao S. Expert consensus on the non-fasting blood lipid detection and clinical application. Chin J Intern Med 2021; 60: 400−405. (In Chinese).

[40] Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1-full report. J Clin Lipidol 2015; 9: 129−169. doi: 10.1016/j.jacl.2015.02.003 [41]

He Z, Yan S. LDL-C measurement: status and development. Exp & Lab Med 2021; 39: 1327−1332. (In Chinese).

[42]

Gotto AM, Jr. , Brinton EA. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease:a working group report and update. J Am Coll Cardiol 2004; 43: 717−724.

[43]

Wilson DP, Jacobson TA, Jones PH, et al. Use of lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol 2019; 13: 374−392.

[44]

Beijing Society of Cardiology. Expert statement on the relationship between lipoprotein(a) and cardiovascular disease risk and clinical management. Chin Circ J 2021; 36: 1158−1167. (In Chinese).

[45]

Wu J, Wang J. Advances in the application and detection of small dense low-density lipoprotein. Chin J Lab Med 2017; 40: 417−420. (In Chinese).

[46] Xu RX, Li S, Li XL, et al. High-density lipoprotein subfractions in relation with the severity of coronary artery disease: A Gensini score assessment. J Clin Lipidol 2015; 9: 26−34. doi: 10.1016/j.jacl.2014.11.003 [47]

Zhang J, Peng H, Li G, et al. Clinical value of remnant lipoproteins and low density lipoprotein cholesterol particle concentration detected by vertical auto profile on the diagnosis of carotid plaque. Chin J Lab Med 2022; 45: 575−581. (In Chinese).

[48] Cholesterol treatment trialists collaboration. efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174, 000 participants in 27 randomised trials. Lancet 2015; 385: 1397−1405. doi: 10.1016/S0140-6736(14)61368-4 [49] Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 2018; 319: 1566−1579. doi: 10.1001/jama.2018.2525 [50]

Liu J, Hong Y, D'Agostino RB, Sr. , et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA 2004; 291: 2591−2599.

[51] Wu Y, Liu X, Li X, et al. Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults. Circulation 2006; 114: 2217−2225. doi: 10.1161/CIRCULATIONAHA.105.607499 [52] Yang X, Li J, Hu D, et al. Predicting the 10-year risks of atherosclerotic cardiovascular disease in Chinese population: The China-PAR Project (Prediction for ASCVD Risk in China). Circulation 2016; 134: 1430−1440. doi: 10.1161/CIRCULATIONAHA.116.022367 [53] Kaasenbrood L, Boekholdt SM, van der Graaf Y, et al. Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a secondary prevention population. Circulation 2016; 134: 1419−1429. doi: 10.1161/CIRCULATIONAHA.116.021314 [54]

Bohula EA, Morrow DA, Giugliano RP, et al. Atherothrombotic risk stratification and ezetimibe for secondary prevention. J Am Coll Cardiol 2017; 69: 911−921.

[55] Sabatine MS, De Ferrari GM, Giugliano RP, et al. Clinical benefit of evolocumab by severity and extent of coronary artery disease: analysis from FOURIER. Circulation 2018; 138: 756−766. doi: 10.1161/CIRCULATIONAHA.118.034309 [56]

Chinese Society of Cardiology of Chinese Medical Association, Cardiovascular Disease Prevention and Rehabilitation Committee of Chinese Association of Rehabilitation Medicine, Cardiovascular Disease Committee of Chinese Association of Gerontology and Geriatrics, Thrombosis Prevention and Treatment Committee of Chinese Medical Doctor Association. Chinese Guideline on the Primary Prevention of Cardiovascular Diseases. Chin J Cardiol 2020; 48: 1000−1038. (In Chinese).

[57] [58]

Zhao S. Lipids Lecture 4: Clinical manifestations and types of hyperlipidemia. Chin J Clinicians 2003; 31: 23−24. (In Chinese).

[59] Expert Dyslipidemia Panel. An international atherosclerosis society position paper: global recommendations for the management of dyslipidemia. J Clin Lipidol 2013; 7: 561−565. doi: 10.1016/j.jacl.2013.10.001 [60] Sun D, Zhou BY, Li S, et al. Genetic basis of index patients with familial hypercholesterolemia in Chinese population: mutation spectrum and genotype-phenotype correlation. Lipids Health Dis 2018; 17: 252. doi: 10.1186/s12944-018-0900-8 [61] Cao YX, Sun D, Liu HH, et al. Improvement of definite diagnosis of familial hypercholesterolemia using an expanding genetic analysis. JACC Asia 2021; 1: 82−89. doi: 10.1016/j.jacasi.2021.04.001 [62] Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34: 3478−3490a. doi: 10.1093/eurheartj/eht273 [63] Sharifi M, Rakhit RD, Humphries SE, Nair D. Cardiovascular risk stratification in familial hypercholesterolaemia. Heart 2016; 102: 1003−1008. doi: 10.1136/heartjnl-2015-308845 [64] Willer CJ, Schmidt EM, Sengupta S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet 2013; 45: 1274−1283. doi: 10.1038/ng.2797 [65] Hegele RA, Ginsberg HN, Chapman MJ, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol 2014; 2: 655−666. doi: 10.1016/S2213-8587(13)70191-8 [66] [67] Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA 2016; 316: 1289−1297. doi: 10.1001/jama.2016.13985 [68] Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012; 307: 1302−1309. doi: 10.1001/jama.2012.366 [69] Thanassoulis G, Williams K, Ye K, et al. Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials. J Am Heart Assoc 2014; 3: e000759. doi: 10.1161/JAHA.113.000759 [70] Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302: 412−423. doi: 10.1001/jama.2009.1063 [71] Willeit P, Kiechl S, Kronenberg F, et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. J Am Coll Cardiol 2014; 64: 851−860. doi: 10.1016/j.jacc.2014.03.061 [72] Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195−2207. doi: 10.1056/NEJMoa0807646 [73] Cholesterol Treatment Trialists Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet 2010; 376: 1670−1681. doi: 10.1016/S0140-6736(10)61350-5 [74]

Bangalore S, Fayyad R, Kastelein JJ, et al. 2013 Cholesterol guidelines revisited: percent LDL cholesterol reduction or attained LDL cholesterol level or both for prognosis? Am J Med 2016; 129: 384-391.

[75] Ridker PM, Mora S, Rose L, Group JTS. Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur Heart J 2016; 37: 1373−1379. doi: 10.1093/eurheartj/ehw046 [76] Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387−2397. doi: 10.1056/NEJMoa1410489 [77] Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018; 379: 2097−2107. doi: 10.1056/NEJMoa1801174 [78] Wang Y, Feng L, Zeng G, et al. Effects of cuisine-based chinese heart-healthy diet in lowering blood pressure among adults in China: multicenter, single-blind, randomized, parallel controlled feeding trial. Circulation 2022; 146: 303−315. doi: 10.1161/CIRCULATIONAHA.122.059045 [79] Ginsberg HN, Karmally W, Siddiqui M, et al. A dose-response study of the effects of dietary cholesterol on fasting and postprandial lipid and lipoprotein metabolism in healthy young men. Arterioscler Thromb 1994; 14: 576−586. doi: 10.1161/01.ATV.14.4.576 [80] Ginsberg HN, Karmally W, Siddiqui M, et al. Increases in dietary cholesterol are associated with modest increases in both LDL and HDL cholesterol in healthy young women. Arterioscler Thromb Vasc Biol 1995; 15: 169−178. doi: 10.1161/01.ATV.15.2.169 [81] Tanasescu M, Cho E, Manson JE, Hu FB. Dietary fat and cholesterol and the risk of cardiovascular disease among women with type 2 diabetes. Am J Clin Nutr 2004; 79: 999−1005. doi: 10.1093/ajcn/79.6.999 [82] Djousse L, Gaziano JM, Buring JE, Lee IM. Egg consumption and risk of type 2 diabetes in men and women. Diabetes Care 2009; 32: 295−300. doi: 10.2337/dc08-1271 [83] Zhong VW, Van Horn L, Cornelis MC, et al. Associations of dietary cholesterol or egg consumption with incident cardiovascular disease and mortality. JAMA 2019; 321: 1081−1095. doi: 10.1001/jama.2019.1572 [84] Zhao SP, Yu BL, Peng DQ, Huo Y. The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial. Atherosclerosis 2014; 233: 707−712. doi: 10.1016/j.atherosclerosis.2013.12.003 [85]

Collaborative Group on Xuezhikang for Secondary Prevention of Coronary Artery Disease. China Coronary Secondary Prevention Study (CCSPS). Chin J Cardiol 2005; 33: 109−115. (In Chinese).

[86]